Stocks · News reference
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lawrence Erik Kurzius, Director at Elanco Animal Health, purchased 40,000 shares at $23.40 per share on August 20, 2026, expanding his direct holdings by 27%. The insider purchase signals confidence in the company, with analysts showing strong bullish sentiment—89% of 18 analysts rate it a buy with a median 12-month price target of $32, representing potential 31% upside.
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal
Major M&A deals include Flex buys EPC Power for $4.4 Billion, KKR acquires A1 Garage Door, Starman Optical Buys GoPro.
Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.